These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 2948607)

  • 41. [Treatment with the LH-RH agonist (Zoladex depot) in patients with puberty praecox].
    Bassi F; Serio M
    Drugs Exp Clin Res; 1990; 16 Suppl():33-7. PubMed ID: 2150502
    [No Abstract]   [Full Text] [Related]  

  • 42. The combination of a depot gonadotrophin releasing hormone agonist and cyclical hormone replacement therapy for dysfunctional uterine bleeding.
    Thomas EJ; Okuda KJ; Thomas NM
    Br J Obstet Gynaecol; 1991 Nov; 98(11):1155-9. PubMed ID: 1836959
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Treatment of advanced prostatic carcinoma with a depot LH-RH analog (ICI 118630)].
    Grifoni R; Pierangeli T
    Minerva Urol Nefrol; 1989; 41(1):5-10. PubMed ID: 2527415
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Differential effects of GnRH analogs on androgen concentrations in females].
    Wirth U; Rossmanith WG; Sasse V; Lauritzen C
    Gynakol Rundsch; 1991; 31 Suppl 2():400-2. PubMed ID: 1838737
    [No Abstract]   [Full Text] [Related]  

  • 45. Zoladex: a sustained-release, monthly luteinizing hormone-releasing hormone analogue for the treatment of advanced prostate cancer.
    Ahmann FR; Citrin DL; deHaan HA; Guinan P; Jordan VC; Kreis W; Scott M; Trump DL
    J Clin Oncol; 1987 Jun; 5(6):912-7. PubMed ID: 2953870
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Phase I study with LH-RH agonist, ICI 118630].
    Usami M; Kotake T; Sonoda T
    Hinyokika Kiyo; 1986 Mar; 32(3):493-501. PubMed ID: 2942018
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Goserelin. A review of its pharmacodynamic and pharmacokinetic properties, and clinical use in sex hormone-related conditions.
    Chrisp P; Goa KL
    Drugs; 1991 Feb; 41(2):254-88. PubMed ID: 1709853
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pharmacokinetics and Bioavailability of the GnRH Analogs in the Form of Solution and Zn
    Suszka-Świtek A; Ryszka F; Dolińska B; Dec R; Danch A; Filipczyk Ł; Wiaderkiewicz R
    Eur J Drug Metab Pharmacokinet; 2017 Apr; 42(2):251-259. PubMed ID: 27180066
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Response to treatment with an analog of the luteinizing-hormone-releasing hormone in a patient with pulmonary lymphangioleiomyomatosis.
    Rossi GA; Balbi B; Oddera S; Lantero S; Ravazzoni C
    Am Rev Respir Dis; 1991 Jan; 143(1):174-6. PubMed ID: 1824744
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Suppression of follicular maturation by infusion of a luteinizing hormone-releasing hormone agonist starting during the late luteal phase in the stumptailed macaque monkey.
    Fraser HM; Sandow J
    J Clin Endocrinol Metab; 1985 Mar; 60(3):579-84. PubMed ID: 3919049
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Protection of spermatogenesis in rats from the cytotoxic procarbazine by the depot formulation of Zoladex, a gonadotropin-releasing hormone agonist.
    Ward JA; Robinson J; Furr BJ; Shalet SM; Morris ID
    Cancer Res; 1990 Feb; 50(3):568-74. PubMed ID: 2137024
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Zoladex in prostatic carcinoma].
    Di Silverio F; Serio M
    Drugs Exp Clin Res; 1990; 16 Suppl():19-29. PubMed ID: 2150501
    [No Abstract]   [Full Text] [Related]  

  • 53. [Clinical effect of slow release (depot) formulation of the LH-RH analogue ICI 118630 (Zoladex) in patients with prostatic carcinoma].
    Usami M; Kotake T; Matsuda M; Okajima E; Osafune M; Sonoda T
    Hinyokika Kiyo; 1987 Jan; 33(1):141-50. PubMed ID: 2953179
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Gonadotropin and gonadal steroid release in response to a gonadotropin-releasing hormone agonist in Gqalpha and G11alpha knockout mice.
    Stanislaus D; Janovick JA; Ji T; Wilkie TM; Offermanns S; Conn PM
    Endocrinology; 1998 Jun; 139(6):2710-7. PubMed ID: 9607776
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Antithrombin III concentration, thrombosis, and treatment with luteinising hormone releasing hormone agonist in prostatic carcinoma.
    Varenhorst E; Svensson M; Hjertberg H; Malmqvist E
    Br Med J (Clin Res Ed); 1986 Apr; 292(6525):935-6. PubMed ID: 2938662
    [No Abstract]   [Full Text] [Related]  

  • 56. Biodegradable polymers for the sustained release of peptides.
    Hutchinson FG; Furr BJ
    Biochem Soc Trans; 1985 Apr; 13(2):520-3. PubMed ID: 3160619
    [No Abstract]   [Full Text] [Related]  

  • 57. Gonadotropin releasing hormone agonist treatment for severe menorrhagia in patients with contraindications to surgery.
    Vercellini P; Ferrari A; D'Alberton A; Motta T; Maggi R; Molteni P
    Eur J Obstet Gynecol Reprod Biol; 1992 Jun; 45(1):70-2. PubMed ID: 1535604
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Long-term effects of buserelin on plasma testosterone and luteinising hormone concentrations.
    Lock MT; de Jong FH; Chadha DR; Schröder FH
    Lancet; 1985 Nov; 2(8466):1236-7. PubMed ID: 2866306
    [No Abstract]   [Full Text] [Related]  

  • 59. Pregnancy outcome following early exposure to maternal luteinizing-hormone-releasing hormone agonist (buserelin).
    Dicker D; Goldman JA; Vagman I; Eckstein N; Ayalon D
    Hum Reprod; 1989 Apr; 4(3):250-1. PubMed ID: 2497132
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Catamenial epilepsy and goserelin.
    Haider Y; Barnett DB
    Lancet; 1991 Dec; 338(8781):1530. PubMed ID: 1683955
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.